Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Smith, Toby; Maidment, Ian; Hebding, Jennifer; Madzima, Tairo; Cheater, Francine; Cross, Jane; Poland, Fiona; White, Jacqueline; Young, John; Fox, Chris (2014)
Languages: English
Types: Article
Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports. Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications . Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence. Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders ( prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders ( prevalence 74%) and ischaemic cerebrovascular disease ( prevalence 53%) were most frequently seen. Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Thomas K, Stobbart Rowlands M, Giles L. Meeting the prime minister's dementia challenge: improving care and increasing acp discussions for people with dementia following the gold standards framework (gsf) dementia care training programme. BMJ Support Palliat Care 2013; 3: 288-9.
    • 2. Helvik AS, Engedal K, Benth JS, Selbaek G. A 52 month follow-up of functional decline in nursing home residents - degree of dementia contributes. BMC Geriatr 2014; 14: 45.
    • 3. Healthcare at Home. Understanding out of hospital dementia care report. 2011. Accessed on 16th April 2014. Available at: http://www.hah.co.uk/media-centre/publications/dementia-report
    • 4. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-32.
    • 5. Critical Appraisal Skills Programme - Randomised Controlled Trial Tool. Accessed on 3rd January 2014. Available at: http://www.casp-uk.net/#!casp-tools-checklists/c18f8
    • 6. Iwasaki K, Kobayashi S, Chimura Y et al. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia. J Am Geriatr Soc; 52:1518-21.
    • 7. Ihl R, Tribanek M, Bachinskaya N. Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial. J Neurol Sci 2010; 299: 184-7.
    • 8. Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-15.
    • 9. Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest 2008; 133: 677-83.
    • 10. Scarpini E, Bruno G, Zappalà G et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis 2011; 26: 211-20.
    • 11. del Ser T, Steinwachs KC, Gertz HJ et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 2013; 33: 205-15.
    • 12. Stenvall M, Berggren M, Lundström M, Gustafson Y, Olofsson B. A multidisciplinary intervention program improved the outcome after hip fracture for people with dementia--subgroup analyses of a randomized controlled trial. Arch Gerontol Geriatr 2012; 54: e284-9.
    • 13. Trzepacz PT, Cummings J, Konechnik T et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr 2013; 25: 707-19.
    • 14. Scheltens P, Kamphuis PJ, Verhey FR et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement 2010; 6: 1-10.e1.
    • 15. Eckert KA, Shi Z, Taylor AW, Wittert G, Price K, Goldney RD. Learning from an epidemiological, population-based study on prescribed medicine use in adults. Pharmacoepidemiol Drug Saf 2013; 22: 271-7.
    • 16. Kaur G, Smyth RL, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. Trials 2012; 13: 218. Trzepacz [13] n = 132 F = 67/132 (50.8%) Treatment group: M =65/132 n=63 (49.2%)
    • 1. Probable AD with NINCDS- Treatment group: ADRDA or DSM IV-TR MMSE = 16.0 (6.1)
    • 2. MMSE = 6-26 ADAS-cog14 = 43.3 (20.4)
    • 3. NPI-10 = ≥ 10 NPI-10 = 31.9 (16.7)
    • 4. NPI-4-A/A = ≥4 NPI-4-A/A = 18.8 (8.7)
    • 5. CT/MRI consistent with dx
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article